GlassScriptPhysician profile
Erica Hobson
NPI 1124652805
$9,466.87
in general payments reported to CMS, 2019-2025
65 companies · $39.56 in 2025
The $39.56 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,628 · 2022: $2,856 · 2023: $3,234 · 2024: $709 · 2025: $39.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,961.49 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $832.21 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $579.19 | 2021-2024 | Tagrisso, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $577.38 | 2021-2024 | Reblozyl, Opdualag |
| Pfizer INC. | $508.19 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $472.22 | 2021-2023 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $465.73 | 2021-2024 | Monjuvi, Pemazyre, Jakafi |
| Glaxosmithkline, LLC. | $341.37 | 2021-2023 | Benlysta, Jemperli, Zejula |
| Beigene USA, INC. | $338.64 | 2021-2023 | Brukinsa |
| Celgene Corporation | $330.01 | 2021-2023 | Pomalyst, Reblozyl |
| Astellas Pharma US INC | $329.78 | 2021-2023 | Padcev |
| Sobi, INC | $323.05 | 2022-2024 | |
| Abbvie INC. | $302.31 | 2022-2025 | |
| Eisai INC. | $259.25 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.67 | 2021-2023 | |
| Janssen Biotech, INC. | $248.72 | 2021-2025 | Talvey |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Hobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.